Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome

@article{Keszthelyi2014SerotonergicRO,
  title={Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome},
  author={Daniel Keszthelyi and Freddy J. Troost and Daisy M.A.E. Jonkers and H. M. Eijk and Patrick J. Lindsey and Jan Dekker and Wim A. Buurman and Ad A. M. Masclee},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2014},
  volume={40}
}
Alterations in serotonergic (5‐HT) metabolism and/or intestinal integrity have been associated with irritable bowel syndrome (IBS). 

Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism – a preliminary study

  • D. KeszthelyiF. Troost A. Masclee
  • Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2015
TLDR
The aim of this preliminary study was to assess the effect of the direct precursor of 5‐HT, 5‐hydroxytryptophan (5‐HTP), on systemic 5-HT metabolites and visceral perception and to assess potential differential responses between IBS and controls.

Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders

TLDR
Intestinal permeability has been studied in small groups of IBS patients with contrasting findings and it is necessary to select patients with high intestinal permeability for IBS treatment.

Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea‐predominant irritable bowel syndrome: a preliminary explorative study

TLDR
Pre‐clinical evidence indicates that nerve growth factor (NGF) mediates visceral hypersensitivity and gut barrier dysfunction, via interactions with mast cells and sensory nerve fibres.

Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome

  • Z. MujagicD. Jonkers A. Masclee
  • Medicine, Biology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2017
Increased visceral sensitivity is observed in up to 60% of patients with Irritable Bowel Syndrome (IBS). Mucosal inflammation, altered neuroendocrine activity and intraluminal metabolic processes may

Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome

TLDR
Current knowledge and recent progress in understanding microbiome–serotonin interaction in IBS cases are summarized, which suggests the manipulation of the gut microbiota may be an alternative treatment strategy.

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review

TLDR
The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function, especially in the IBS-D and PI-IBS subtype.

Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions.

TLDR
Current knowledge and unanswered questions in the pathobiology of the chemical and molecular factors in IBS are reviewed and how they may influence hypervigilance in the central nervous system in patients with IBS is appraised.

Diverse Effects of Gut-Derived Serotonin in Intestinal Inflammation.

TLDR
The current review aims to provide an update on the role of enteric 5-HT and its immune mediators in the context of intestinal inflammation.

Editorial: abnormal permeability and altered mucosal serotonin metabolism in the irritable bowel syndrome – is there a link?

  • R. Spiller
  • Medicine
    Alimentary pharmacology & therapeutics
  • 2014
TLDR
This study was designed to assess health utilities and patient-reported outcomes during treatment with sofosbuvir regimens in a clinical trial setting and it is important to point out that this issue should be addressed in the future, after approval of these regimens, using data collected in clinical practice setting.

References

SHOWING 1-10 OF 44 REFERENCES

Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome

TLDR
Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology, but numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients.

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

  • H. DuPont
  • Medicine
    Alimentary pharmacology & therapeutics
  • 2014
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disease with a substantial social and economic burden. Treatment options remain limited and research on the aetiology and

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea‐predominant irritable bowel syndrome

TLDR
The intestinal permeability is increased in patients with diarrhoea‐predominant irritable bowel syndrome (D‐IBS) and this increased permeability increases the likelihood that the patient will have diarrhea and/or constipation.

Intestinal permeability and irritable bowel syndrome

  • M. CamilleriH. Gorman
  • Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2007
TLDR
While a subgroup of patients with IBS appears to have evidence of increased intestinal permeability, improvements in the methods and validation are key to further research in this field in order to better understand intestinal barrier functions in IBS.

Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.

TLDR
Findings support the assertion that disordered gastrointestinal function in IBS involves changes intrinsic to the bowel and suggest that shared defects in 5-HT signaling may underlie the altered motility, secretion, and sensation.

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.

TLDR
The role of the healthy intestinal epithelium as a barrier between the lumen and the rest of the body with a focus on tight junctions is summarized to explore how this increased permeability may elicit immune responses that affect afferent nerves, resulting in the pain associated with IBS.

Serotonin in the gastrointestinal tract

  • M. Camilleri
  • Medicine, Biology
    Current opinion in endocrinology, diabetes, and obesity
  • 2009
TLDR
Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is likely to enhance understanding of the mechanisms and treatment of these diseases.

Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome

TLDR
In patients with IBS, 5-HT spontaneous release was significantly increased irrespective of bowel habit and correlated with mast cell counts and the severity of abdominal pain, suggesting that increased 5-hydroxytryptamine release contributes to development of abdominalPain in IBS.

Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation.

TLDR
Platelet SERT is reduced in IBS-D and associated with reduced levels of SERT mRNA and duodenal immune activation and correlated inversely with platelet uptake of 5-HT.